(2R,3R)-Chlorpheg

Discontinued Product

(2R,3R)-Chlorpheg (Cat. No. 0816) has been withdrawn from sale for commercial reasons.
Description: Inactive isomer of (0134)
Chemical Name: (2R,3R)-b-p-Chlorophenylglutamic acid
Datasheet
Citations
Reviews
Literature (3)

Biological Activity for (2R,3R)-Chlorpheg

Inactive stereoisomer.

Technical Data for (2R,3R)-Chlorpheg

M. Wt 257.67
Storage Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (2R,3R)-Chlorpheg

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

Keywords: (2R,3R)-Chlorpheg, (2R,3R)-Chlorpheg supplier, Glutamate, Transporters, 0816, Tocris Bioscience

Citations for (2R,3R)-Chlorpheg

Citations are publications that use Tocris products.

Currently there are no citations for (2R,3R)-Chlorpheg.

Reviews for (2R,3R)-Chlorpheg

There are currently no reviews for this product. Be the first to review (2R,3R)-Chlorpheg and earn rewards!

Have you used (2R,3R)-Chlorpheg?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Schizophrenia Poster

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.